MYC and neoplasm: Although encouraging results in tumour reduction have been obtained using methods to preselect for ESCs that differentiate along a cardiac lineage, or to preserve pluripotency in absence of Myc for iPS cells, a mere reduction in tumour incidence will not be sufficient to justify clinical trials.